Skip to main content

Table 2 Correlation between the IL-6, CRP and clinicopathological parameters

From: Clinical significances of preoperative serum interleukin-6 and C-reactive protein level in operable gastric cancer

 

IL-6

CRP

 

Median ± SD

r

P

Median ± SD

R

P

Total

pg/ml

  

(mg/dl)

  

Gender

      

   Male

6.83 ± 7.34

0.082

0.385

0.11 ± 0.25

-0.076

0.421

   Female

7.07 ± 12.30

  

0.06 ± 0.43

  

Age

      

   <60

6.48 ± 12.26

0.205

0.028

0.07 ± 0.30

0.152

0.104

   ≥ 60

7.31 ± 5.56

  

0.11 ± 0.38

  

Tumor size

      

   <5 cm

6.48 ± 5.04

0.235

0.012

0.09 ± 0.28

0.081

0.389

   ≥5 cm

7.56 ± 12.93

  

0.09 ± 0.39

  

Tumor depth

      

   pT1

6.25 ± 1.41

0.387

0.000

0.05 ± 0.10

0.311

0.001

   pT2

6.60 ± 5.42

  

0.07 ± 0.31

  

   pT3

7.62 ± 16.02

  

0.17 ± 0.36

  

   pT4

9.76 ± 6.06

  

0.64 ± 0.64

  

LN meta

      

   N0

6.36 ± 5.61

0.322

0.000

0.06 ± 0.30

0.211

0.024

   N1

7.70 ± 13.99

  

0.11 ± 0.36

  

   N2

6.83 ± 2.10

  

0.09 ± 0.08

  

   N3

7.80 ± 6.96

  

0.19 ± 0.51

  

   (N1–N3)

7.56 ± 11.24

0.338

0.000

0.11 ± 0.35

0.212

0.023

TNM stage

      

   I

7.36 ± 5.52

0.425

0.000

0.06 ± 0.29

0.326

0.000

   II

7.66 ± 2.24

  

0.07 ± 0.15

  

   III

11.87 ± 14.90

  

0.12 ± 0.30

  

   IV

13.92 ± 10.76

  

0.39 ± 0.50

  

Peritoneal

      

   Metastasis(-)

6,83 ± 8.83

0.233

0.012

0.08 ± 0.29

0.175

0.061

   Metastasis(+)

23.70 ± 14.55

  

0.41 ± 0.69

  
  1. r, P: Spearman rho correlation, IL-6: interleukin-6, CRP: C-reactive protein, LN: lymph node, TNM (6th AJCC Stage Groupings: The staging systems; Primary tumor, regional LN, metastasis)